About APCI

APCI logo

Not a member?
Join today!

(800) 532-2724

Since 1984, APCI has been the ‘united voice of independent pharmacy’

APCI began as a small buying group for a limited number of independent pharmacies in central Alabama. Since that time, the cooperative has grown to more than 1,800 members pharmacies in 26 states, and provides its members with a wide range of products and services.

Our mission is to represent the economic and professional interests of independent pharmacies by providing leadership, vision, and a collective voice for our members in the healthcare marketplace. Our goal is to level the playing field for our member pharmacies by providing innovative, targeted programs to benefit our entire membership.

16

Aug

2016

Express Scripts: Amerigroup Community Care & Empire BCBS HealthPlus Formulary Updates REMINDER

Effective: August 1, 2015

This is a reminder that Amerigroup Community Care has made a change to the Preferred Drug List (PDL) in the states of Georgia, New Jersey and Nevada. Likewise, Empire BlueCross BlueShield HealthPlus (Empire) in New York has made a change to its PDL. These changes became effective August 1, 2016.

In the table below, medications listed in the left-hand column are no longer included as preferred drugs under the Amerigroup plans in Georgia, New Jersey and Nevada, and under the Empire plan in New York.

16

Aug

2016

OptumRx: IMPORTANT INFORMATION REGARDING Recall of Liquid Products by PharmaTech

Effective: August 8, 2016

On August 8, 2016, PharmaTech announced a recall of all liquid products produced from October 20, 2015 through July 15, 2016 because of a risk of product contamination with Burkholderia cepacia. Per PharmaTech, use of a product with B. cepacia may result in serious infections that could be life-threatening in patients with compromised immune systems and in patients with chronic lung conditions such as cystic fibrosis. OptumRx notified members who may be affected by this recall. These members were advised not to use the recalled product. In the future, these members may inquire about one of the liquid product prescription(s) you dispensed. You may also call PharmaTech at 754-701-8320 (8 a.m. – 5 p.m. EST, Monday through Friday) for more information about this recall.

16

Aug

2016

US Script: URGENT FDA RECALL NOTICE: Liquid Drug and Dietary Supplement Products by PharmaTech

Effective: Immediately

PharmaTech, LLC is voluntarily recalling all liquid drug and dietary supplement products due to a potential risk of product contamination with Burkholderia cepacia (B. cepacia). See the press release for a complete listing of affected products. If a product contains B. cepacia, its use could result in infections in patients with compromised immune systems and in patients with chronic lung conditions such as cystic fibrosis. Some of these infections may be serious or even life-threatening in the at risk patient population. BACKGROUND: This recall affects all liquid products from October 20, 2015 through July 15, 2016. Please immediately check your medical supplies, quarantine any liquid drug and dietary supplement products by PharmaTech, and do not administer them. Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program: • Complete and submit the report Online: www.fda.gov/MedWatch/report • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178 Thank you for your assistance with this notification. We look forward to working together to provide quality pharmacy services to our members. Please contact the US Script Pharmacy Help Desk for questions: (800) 460-8988

16

Aug

2016

Express Scripts: Mosquito Repellent Update

Effective: June 1,2016

On June 1, 2016 the Centers for Medicare & Medicaid Services (CMS) issued an informational bulletin about Medicaid benefits available for the prevention, detection, and response to the Zika virus. Zika can cause severe birth defects in unborn children whose mothers are infected while pregnant. Because there is not a vaccine to prevent the disease or medicine to treat it, it is important for women to use repellent to protect themselves and unborn babies.

Starting August 9, 2016, Texas will cover select mosquito repellents under the Medicaid Fee For Service (FFS) and managed care organizations (MCO), Children's Health Insurance Plan (CHIP) and Healthy Texas Women programs. Neither the Kidney Health Care (KHC) nor Children with Special Health Care Needs (CSHCN) Services programs will cover these products. The following describes the benefit details, eligibility, benefit specifics, and claims processing for mosquito repellent, and information about Zika virus.

First 684685686687 Last